







an Open Access Journal by MDPI

Adoptive Cell Therapy against Cancers

Guest Editors:

Dr. Lei Wang

Department of Internal Medicine V, Universitätsklinikum Heidelberg, Heidelberg, Germany

Dr. Sanmei Wang

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China

Dr. Wenjie Gong

Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

Deadline for manuscript submissions:

closed (15 March 2023)

Message from the Guest Editors

Adoptive cell therapy (ACT), especially, chimeric antigen receptor (CAR) T cell therapy, is rapidly growing and have revolutionized the field of immunotherapy for cancer, showing promise in the treatment of cancer patients, leading to durable responses and, in some cases, cure. Barriers to effective ACT include time-consuming and labintensive manufacturing, complex logistics, severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration, and so on. To overcome these hurdles, several strategies, from screening the best starting material, developing novel CAR or TCR structures and improving the manufacturing process up to combining ACT with other anti-tumor agents, could be considered to optimize the clinical efficacy of ACT.

This Special Issue aims to cover recent advances in adoptive cell therapy including manufacturing, method validation for product specification, logistics study, novel CAR design, combination therapy and clinical trials and therefore seeks for review or original manuscripts addressing one of the aforementioned (or related) topics.

We look forward to receiving your contributions.













an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. Cells encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Cell Biology*) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Contact Us